Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.38 |
| ▸ | AXL | P30530 | 16/20 | 0.38 |
| ▸ | MERTK | Q12866 | 16/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 12/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101359 | 0.89 | AXL (0.50) | METAXLMERTKTYRO3 | |
| SCHEMBL3103490 | 0.85 | AXL (0.44) | METAXLMERTKTYRO3 | |
| SCHEMBL3101737 | 0.84 | AXL (0.48) | METAXLMERTKTYRO3 | |
| SCHEMBL3104308 | 0.80 | AXL (0.57) | METAXLMERTKTYRO3 | |
| SCHEMBL3108790 | 0.78 | AXL (0.49) | METAXLMERTKTYRO3 | |
| SCHEMBL3104234 | 0.77 | AXL (0.51) | METAXLMERTKTYRO3 | |
| SCHEMBL3112956 | 0.77 | SMN1; SMN2 (0.44) | AXLKCNK3KDM4EMEN1KMT2A | |
| SCHEMBL3100095 | 0.77 | AXL (0.55) | METAXLMERTKTYRO3 | |
| SCHEMBL3109135 | 0.76 | AXL (0.54) | METAXLMERTKTYRO3 | |
| SCHEMBL3101814 | 0.76 | AXL (0.54) | METAXLMERTKTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MET 357/4885AXL 117/4885MERTK 285/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MET 357/4885AXL 117/4885MERTK 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.